OrganoClick: Weaker Q4 likely, but set up for a stronger H1 - ABG
Q4e sales of SEK 23.9m, down 14% y-o-y, EBIT SEK -7m (-6m) NW&FT and FW weak while momentum continues in GC&MP Hopeful of a recovery in '25e, lower interest rates to drive NW&FT
ANNONS
Q4 expectations
In the company's seasonally weakest quarter, Q4, we expect sales of SEK 23.9m, down 14% y-o-y, as the NW&FT and FW segments continue to face headwinds from weak end-markets, while GC&MP continues its strong performance thanks to good product momentum with new customer launches during the year. On EBIT, we have SEK -7m (-6m), down only slightly y-o-y due to lower sales but improved cost control.
